<SEC-DOCUMENT>0001129928-22-000052-index.html : 20220507
<SEC-HEADER>0001129928-22-000052.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505162037
ACCESSION NUMBER:		0001129928-22-000052
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		22896631

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q12022form6-k.htm
<DESCRIPTION>2022 FIRST QUARTER 6-K
<TEXT>
Document 1 - file: q12022form6-k.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsmarch312022.htm
<DESCRIPTION>EX-99.1 2022 FIRST QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
Document 2 - file: ex991-interimfsmarch312022.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q12022mda.htm
<DESCRIPTION>EX-99.2 2022 FIRST QUARTER MD&A
<TEXT>
Document 3 - file: ex992-q12022mda.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q12022certificationx.htm
<DESCRIPTION>EX-99.3 Q1 2022 CERTIFICATION CEO
<TEXT>
Document 4 - file: ex993-q12022certificationx.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q12022certificationx.htm
<DESCRIPTION>EX-99.4 Q1 2022 CERTIFICATION CFO
<TEXT>
Document 5 - file: ex994-q12022certificationx.htm

</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogotaglineblueaa.jpg
<TEXT>
Document 6 - file: oncolyticslogotaglineblueaa.jpg

</DOCUMENT>
</SEC-DOCUMENT>